HTA Assessment of Clinical-care Pathways: Peritoneal Dialysis Vs Hemodialysis - Content Summary.

Peritoneal dialysis (PD) is used in Italy for less than 10% of patients on dialysis, with considerable inter-regional variability. The ALTEMS research using HTA methodology set out to assess whether this is justified on economic grounds. Effectiveness measured in terms of Quality Adjusted Life Years (QALY) is 1.20 for PD compared to the 0.94 of hospital hemodialysis (HD). In terms of cost-utility analysis, PD is therefore "dominant" as it is more effective and less costly, and as a result is the treatment of choice from both clinical and economic points of view, as well as from both social and SSN perspectives. On Budget Impact Analysis (BIA), the real annual cost per patient from the social perspective is € 24,142 for PD and € 42,231 for HD. A hypothetical greater use of PD, with an annual increase of at least 5% of patients on PD, would result in savings over a 5-year period of close to 100 million euro.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-10-24
DOI
https://doi.org/10.69097/42-05-2025-04
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HTA Assessment of Clinical-care Pathways: Peritoneal Dialysis Vs Hemodialysis - Content Summary.

Silvia D'Alonzo, Debora Antonini, Maurizio Gallieni, Loris Neri et al.
PubMed
Health Systems, Economic Evaluations, Quality of Life
article

HTA Assessment of Clinical-care Pathways: Peritoneal Dialysis Vs Hemodialysis - Content Summary.

Silvia D'Alonzo, Debora Antonini, Maurizio Gallieni, Loris Neri, Franco Citterio, Valerio Vizzardi, Giuseppe Arbia, Marco Oradei, Giuliano Brunori, Luca De Nicola, Alessandra Fiore
article en

Abstract

Peritoneal dialysis (PD) is used in Italy for less than 10% of patients on dialysis, with considerable inter-regional variability. The ALTEMS research using HTA methodology set out to assess whether this is justified on economic grounds. Effectiveness measured in terms of Quality Adjusted Life Years (QALY) is 1.20 for PD compared to the 0.94 of hospital hemodialysis (HD). In terms of cost-utility analysis, PD is therefore "dominant" as it is more effective and less costly, and as a result is the treatment of choice from both clinical and economic points of view, as well as from both social and SSN perspectives. On Budget Impact Analysis (BIA), the real annual cost per patient from the social perspective is € 24,142 for PD and € 42,231 for HD. A hypothetical greater use of PD, with an annual increase of at least 5% of patients on PD, would result in savings over a 5-year period of close to 100 million euro.

PubMedVol. 42(5)
Università Cattolica del Sacro Cuore (IT), Agostino Gemelli University Polyclinic (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Provincia Autonoma di Trento (IT), University of Campania "Luigi Vanvitelli" (IT), ASST Fatebenefratelli Sacco (IT), Ospedale San Pietro Fatebenefratelli (IT)
Openalex Percentile: Top 59%
Health Systems, Economic Evaluations, Quality of Life
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HTA Assessment of Clinical-care Pathways: Peritoneal Dialysis Vs Hemodialysis - Content Summary. — Silvia D'Alonzo, Debora Antonini, et al. · PubMed (2025) | TGRS Research Map | TGRS